[go: up one dir, main page]

AR003175A1 - A PHARMACEUTICAL COMPOSITION COMPRISING A PHARMACEUTICALLY ACCEPTABLE CARRIER AND A CHEMOTHERAPEUTICAL AGENT AND A TRIAZOL, SUCH A PHARMACEUTICAL COMPOSITION, WHICH INCLUDES A POTENTIAL, 1-POTENTIAL USE BY A CHEMICAL DRIVER, AND USE AND SAID TRIAZOLE TO TREAT CANCER, TUMORS OR VIRAL INFECTIONS IN MAMMALS OF HOT BLOOD - Google Patents

A PHARMACEUTICAL COMPOSITION COMPRISING A PHARMACEUTICALLY ACCEPTABLE CARRIER AND A CHEMOTHERAPEUTICAL AGENT AND A TRIAZOL, SUCH A PHARMACEUTICAL COMPOSITION, WHICH INCLUDES A POTENTIAL, 1-POTENTIAL USE BY A CHEMICAL DRIVER, AND USE AND SAID TRIAZOLE TO TREAT CANCER, TUMORS OR VIRAL INFECTIONS IN MAMMALS OF HOT BLOOD

Info

Publication number
AR003175A1
AR003175A1 ARP960103860A AR10386096A AR003175A1 AR 003175 A1 AR003175 A1 AR 003175A1 AR P960103860 A ARP960103860 A AR P960103860A AR 10386096 A AR10386096 A AR 10386096A AR 003175 A1 AR003175 A1 AR 003175A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
potential
triazol
tumors
mammals
Prior art date
Application number
ARP960103860A
Other languages
Spanish (es)
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/674,180 external-priority patent/US5908855A/en
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of AR003175A1 publication Critical patent/AR003175A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se presenta una composición farmacéutica para el tratamiento de cánceres y tumores en mamíferos, que comprende 2-(2,4-difluorofenil)-1,3-bis(1H-1,2,4-triazol-1-il)propan-2-ol y sus derivados. Junto con el 2-(2,4-difluorofenil)-1,3-bis)1H-1,2,4- triazol-1-il)propan-2-ol y sus derivados puede utilizarse unagente quimioterapeútico, como así también potenciadores. El 2-(2,4- difluorofenil)-1,3-bis(1H-1,2,4-triazol-1-il)propan-2-ol y sus derivados puedenserutilizados también para el tratamiento de infecciones virósicas, ya sea solos o en combinación con otros agentes antivirósicos o con un potenciador.A pharmaceutical composition for the treatment of cancers and tumors in mammals is presented, comprising 2- (2,4-difluorophenyl) -1,3-bis (1H-1,2,4-triazol-1-yl) propan-2 -ol and its derivatives. Together with 2- (2,4-difluorophenyl) -1,3-bis) 1H-1,2,4-triazol-1-yl) propan-2-ol and its derivatives, a chemotherapeutic agent can be used, as well as potentiators. . 2- (2,4-Difluorophenyl) -1,3-bis (1H-1,2,4-triazol-1-yl) propan-2-ol and its derivatives can also be used for the treatment of viral infections, either alone or in combination with other antiviral agents or with a booster.

ARP960103860A 1995-08-04 1996-08-02 A PHARMACEUTICAL COMPOSITION COMPRISING A PHARMACEUTICALLY ACCEPTABLE CARRIER AND A CHEMOTHERAPEUTICAL AGENT AND A TRIAZOL, SUCH A PHARMACEUTICAL COMPOSITION, WHICH INCLUDES A POTENTIAL, 1-POTENTIAL USE BY A CHEMICAL DRIVER, AND USE AND SAID TRIAZOLE TO TREAT CANCER, TUMORS OR VIRAL INFECTIONS IN MAMMALS OF HOT BLOOD AR003175A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US188995P 1995-08-04 1995-08-04
US08/674,180 US5908855A (en) 1996-07-16 1996-07-16 Compositions for treating viral infections

Publications (1)

Publication Number Publication Date
AR003175A1 true AR003175A1 (en) 1998-07-08

Family

ID=26669622

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960103860A AR003175A1 (en) 1995-08-04 1996-08-02 A PHARMACEUTICAL COMPOSITION COMPRISING A PHARMACEUTICALLY ACCEPTABLE CARRIER AND A CHEMOTHERAPEUTICAL AGENT AND A TRIAZOL, SUCH A PHARMACEUTICAL COMPOSITION, WHICH INCLUDES A POTENTIAL, 1-POTENTIAL USE BY A CHEMICAL DRIVER, AND USE AND SAID TRIAZOLE TO TREAT CANCER, TUMORS OR VIRAL INFECTIONS IN MAMMALS OF HOT BLOOD

Country Status (18)

Country Link
EP (1) EP0841921A2 (en)
JP (1) JPH11510187A (en)
KR (1) KR19990036138A (en)
CN (1) CN1195288A (en)
AR (1) AR003175A1 (en)
AU (1) AU711966B2 (en)
BR (1) BR9609966A (en)
CA (1) CA2229024A1 (en)
CZ (1) CZ33798A3 (en)
HU (1) HUP9903420A3 (en)
IL (1) IL123095A0 (en)
MX (1) MX9800998A (en)
NO (1) NO980473L (en)
NZ (2) NZ315184A (en)
PL (1) PL324904A1 (en)
SK (1) SK14198A3 (en)
TR (2) TR199801739T2 (en)
WO (1) WO1997005873A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
FR2742405B1 (en) * 1995-12-13 1998-02-27 Cgea Comp Gen Entre Auto DRIVE UNIT COULD BE COUPLED TO A ROLLING SPEAKER AND RESULTING VEHICLE
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
PE11499A1 (en) * 1997-05-16 1999-03-01 Procter & Gamble TREATMENT OF HIV AND CANCER
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
EP2055313B1 (en) * 1998-11-09 2015-04-29 Biogen Idec Inc. Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
US6407105B1 (en) 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US7004915B2 (en) * 2001-08-24 2006-02-28 Kci Licensing, Inc. Negative pressure assisted tissue treatment system
RU2201230C1 (en) * 2001-12-24 2003-03-27 Закрытое акционерное общество "Брынцалов-А" Medicinal agent "flusol" eliciting antifungal effect
EP1895012A1 (en) 2006-08-30 2008-03-05 Universitätsklinikum Freiburg Method for inducing tumor apoptosis by increasing nitric oxide levels
US20120071539A1 (en) * 2006-12-12 2012-03-22 Emory University Compounds and methods for modulating the silencing of a polynucleotide of interest
WO2019185521A1 (en) * 2018-03-26 2019-10-03 Westfälische Wilhelms-Universität Münster Ergosterol-biosynthesis inhibitor and influenza virus infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0196855A3 (en) * 1985-03-29 1989-04-12 Pfizer Inc. Tioconazole and related compounds for prevention of sexually transmitted diseases and control of herpetic infections
BE1004029A6 (en) * 1990-11-22 1992-09-08 Mol Omer De Pharmaceutical compound and pharmaceutical set for the treatment of cancer
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US5665751A (en) * 1995-06-07 1997-09-09 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers

Also Published As

Publication number Publication date
AU6683396A (en) 1997-03-05
SK14198A3 (en) 1999-03-12
WO1997005873A3 (en) 1997-03-27
IL123095A0 (en) 1998-09-24
JPH11510187A (en) 1999-09-07
NZ315184A (en) 2000-05-26
NZ503921A (en) 2002-03-01
CN1195288A (en) 1998-10-07
HUP9903420A2 (en) 2000-03-28
WO1997005873A2 (en) 1997-02-20
NO980473L (en) 1998-04-03
MX9800998A (en) 1998-04-30
BR9609966A (en) 1999-02-02
TR199800270T1 (en) 1998-05-21
TR199801739T2 (en) 1998-12-21
NO980473D0 (en) 1998-02-03
PL324904A1 (en) 1998-06-22
EP0841921A2 (en) 1998-05-20
AU711966B2 (en) 1999-10-28
CA2229024A1 (en) 1997-02-20
KR19990036138A (en) 1999-05-25
CZ33798A3 (en) 1998-06-17
HUP9903420A3 (en) 2001-12-28

Similar Documents

Publication Publication Date Title
AR003175A1 (en) A PHARMACEUTICAL COMPOSITION COMPRISING A PHARMACEUTICALLY ACCEPTABLE CARRIER AND A CHEMOTHERAPEUTICAL AGENT AND A TRIAZOL, SUCH A PHARMACEUTICAL COMPOSITION, WHICH INCLUDES A POTENTIAL, 1-POTENTIAL USE BY A CHEMICAL DRIVER, AND USE AND SAID TRIAZOLE TO TREAT CANCER, TUMORS OR VIRAL INFECTIONS IN MAMMALS OF HOT BLOOD
FR15C0057I1 (en)
GT199800126A (en) COMBINATION THERAPY.
MY116478A (en) Tri-substituted imidazoles having multiple therapeutic properties
ID29930A (en) TRIAZOL COMPOUNDS AND ITS USE
IE821285L (en) Triazole antifungal agents
KR910021398A (en) Triazole Antifungal Agents
ES2130542T3 (en) PROCEDURE FOR PREPARING 1- (2'-DESOXI-2 ', 2'-DIFLUORO-D-RIBOFURANOSIL) -4-AMINOPYRIMIDIN-2-ONA.
TR199801323T2 (en) Use of 1,2,4-triazole derivatives in the manufacture of a drug for the treatment of viral infections.
MX9800944A (en) Use of 1h-1,2,4-triazole derivatives for inhibiting the growth of cancers.
HUP9802629A3 (en) Use of 1,3-bis(1,2,4-triazolyl)propan-2-ol derivatives for the manufacture of pharmaceutical compositions treating cancers
NO168033C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE TRIAZOL AND IMIDAZOL DERIVATIVES.
MX9800945A (en) Use of griseofulvin for inhibiting the growth of cancers.
AR043071A1 (en) USE OF MACROLIDES FOR THE TREATMENT OF CANCER AND MACULAR DEGENERATION AND A PHARMACEUTICAL COMPOSITION
IE831371L (en) 1,2,4-triazole derivatives
SE8304408L (en) DESOXIURIDE DERIVATIVES, THE PROCEDURES FOR THEIR PREPARATION AND THEIR USE AS A MEDICINAL PRODUCT
ES2129893T3 (en) DINUCLEOSIDE-5 ', 5'-PYROPHOSPHATES.
ES2116411T3 (en) THE SULPHATE SALT OF A SUBSTITUTED TRIAZOLE, PHARMACEUTICAL COMPOSITIONS OF THE SAME AND ITS USE IN THERAPY
KR920012049A (en) Fluorine compounds
BR0017046A (en) Use of azoles to prevent skin cancer
EP0367069A3 (en) Substituted bisazoles, process for their preparation and their use as therapeutic agents
ES2170377T3 (en) COMPOSITION CONTAINING QUITOSANA.
ES8704464A1 (en) 4(5)-substituted imidazoles.
ES2184289T3 (en) SUPPLY OF AN IMPROVED ANTI-TARGET AGENT TO SOLID TUMORS AS THE FIRST COMPONENT.
MX9709712A (en) Use of 1,2,4-triazole derivatives for the manufacture of a medicament for the treatment of cancers.

Legal Events

Date Code Title Description
FC Refusal